| Literature DB >> 32192477 |
Nina Zipfel1,2, A Stef Groenewoud3, Benno J W M Rensing4, Edgar J Daeter5, Lea M Dijksman6, Jan-Henk E Dambrink7, Philip J van der Wees3, Gert P Westert3, Paul B van der Nat6.
Abstract
BACKGROUND: Measuring and improving outcomes is a central element of value-based health care. However, selecting improvement interventions based on outcome measures is complex and tools to support the selection process are lacking. The goal was to present strategies for the systematic identification and selection of improvement interventions applied to the case of aortic valve disease and to combine various methods of process and outcome assessment into one integrated approach for quality improvement.Entities:
Keywords: Patient outcomes; Quality improvement; Quality management; Value-based healthcare
Mesh:
Year: 2020 PMID: 32192477 PMCID: PMC7082899 DOI: 10.1186/s12913-020-05090-z
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Flowchart of methodological mixed-method approach. Flowchart of methodological mixed-method approach for (a) the identification of improvement potential and (b) selection of an improvement intervention describing the goals of each step
Fig. 2Example of a causal chain. MUST is the Malnutrition Universal Screening Tool. DSWI is deep sternum wound infection. One star indicates a small impact on outcome measures. Two stars indicate a slightly bigger (intermediate) impact on outcome measures. Three starts represent a large impact on outcome measures
Fig. 3SAVR 30-day mortality for the primary hospital and four MB hospitals over time. Measurably Better data report 2015. Including the number of cases occurred per year for the primary hospital and four Measurably Better hospitals
Fig. 4Cox-regression survival curves within 30 days after procedure. Primary hospital compared to four hospitals corrected for EuroSCORE. Procedural mortality was excluded for this analysis. Analysis starts at 1 day post-procedure. Hospital B (N = 318) (HR 1.79, 95% CI 0.7–4.57, p = 0.224), hospital C (N = 359) (HR 1.26, 95% CI 0.46–3.46, p = 0.661), hospital D (N = 947) (HR 0.79, 95% CI 0.33–1.9, p = 0.592), hospital E (N = 618) (HR 1.2, 95% CI 0.5–2.88, p = 0.694) did not differ significantly from the primary hospital (N = 822) in survival within 30 days after procedure
Univariable and multivariable logistic regression results predicting 30-day mortality
| Treatment | Predictor | Category | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|---|---|
| OR | (95% CI) | OR | (95% CI) | |||||
| SAVR ( | Valve type | Bio prosthetic valve | 1.0 | |||||
| Mechanical valve | 1.5 | (0.32–6.88) | .607 | |||||
| TAVR ( | Access route | Direct aortic | 1.0 | 1.0 | ||||
| Transfemoral | 0.5 | (0.28–0.80) | 0.006 | 0.4 | (0.19–0.75) | 0.005 | ||
| Transapical | 1.4 | (0.83–2.47) | 0.196 | 1.4 | (0.65–2.87) | 0.417 | ||
| Vascular complication | 2.5 | (1.66–3.70) | < 0.001 | 2.9 | (1.92–4.63) | < 0.001 | ||
| Valve re-intervention | 0.8 | (0.19–3.66) | 0.819 | |||||
| Previous heart operation | 0.9 | (0.67–1.45) | 0.932 | |||||
| Previous CVAa | 1.4 | (0.85–2.14) | 0.203 | |||||
| Previous mitral valve stenosis | 0.6 | (0.4–0.96) | 0.033 | 1.4 | (0.84–2.22) | 0.213 | ||
| Hospitalb | Primary hospital | 1.0 | 1.0 | |||||
| A | 0.7 | (0.46–1.19) | 0.214 | 1.0 | (0.56–1.80) | 0.993 | ||
| B | 0.7 | (0.43–0.98) | 0.041 | 0.9 | (0.54–1.47) | 0.658 | ||
| C | 1.1 | (0.7–1.71) | 0.691 | 0.2 | (0.09–0.57) | 0.002 | ||
| D | 0.4 | (0.21–0.76) | 0.005 | 0.2 | (0.06–0.68) | 0.010 | ||
| E | 0.4 | (0.16–1.05) | 0.063 | 0.09 | (0.01–0.70) | 0.021 | ||
| Urgencyc | Elective | 1 | ||||||
| Urgent | 0.8 | (0.48–1.33) | 0.390 | |||||
| Severe left ventricular dysfunction | > 50% | 0.6 | (0.21–1.77) | 0.363 | ||||
| < 50% | 1.0 | (0.33–2.77) | 0.935 | |||||
| Age | 1.0 | (0.98–1.06) | 0.427 | |||||
| Renal dysfunction | 1.6 | (1.13–2.27) | 0.008 | 1.9 | (1.27–2.82) | 0.002 |
aCVA cerebrovascular accident
bAnalysis for Hospital was conducted relative to the primary hospital. Measurably Better data 2015
cUrgency: for urgent operations, no emergency and rescue operations
Results care delivery process analysis
| Treatment | Process Phase | Potential improvement intervention | Impact on outcome |
|---|---|---|---|
| SAVR | Monitoring and preventing | Identify high-risk patients by measuring a Frailty Score | Mortality, Quality of Life |
| Organize a specific pre-operative screening for older patients | None* | ||
| Diagnosing | Introduce a frailty protocol | Quality of Life, mortality | |
| Discuss older patients in a multidisciplinary team | Quality of Life, Mortality | ||
| Introduce a checklist for uniform imaging | Quality of Life, Mortality | ||
| Screen abdominal vascular disease | Mortality | ||
| Screen for long-vein narrowing | Mortality | ||
| Preparing | Adjust the anticoagulation protocol | Mortality | |
| Intervening | Standardize with a protocol for the blood or crystalloid cardioplegia | Mortality | |
| Use of MECCa and improve experience of the operation team | Mortality | ||
| Implant the long-term pacemaker as fast as possible after operation | Mortality | ||
| Recovery/Rehab | Conduct an echocardiography only with indication | Quality of Life | |
| Improve nightly supervision at the ICUb (cultural change) | Mortality, valve re-intervention | ||
| Offer every patient heart rehabilitation program | Quality of Life | ||
| Raise more attention to diet of the patient, practice spirometry | Quality of Life | ||
| Introduce a checklist for the exit consult | Re-intervention | ||
| Monitoring/ Managing | Adjust the medication protocol | Quality of Life | |
| TAVR | Monitoring and preventing | Optimize Frailty identification | None* |
| Introduce home monitoring system for measuring blood pressure (E-Health) | Quality of Life | ||
| Diagnosis | Introduce more frequent TAVR team meetings to discuss patients | Mortality, Quality of Life | |
| Improve hospital logistics (with the support of the Lean method) | Mortality, Quality of Life | ||
| Assure that an echo is always available before diagnosis | Complications | ||
| More frequent TAVR Team meetings to discuss patients | Mortality | ||
| Digitalize the treatment plan | Mortality | ||
| Involve an anesthetist in the TAVR Team meetings | Mortality | ||
| Introduce a diagnosis checklist for treatment choices | None* | ||
| Preparing | Conduct pre-operative check-up and CT-scan on the same day | Waiting-times | |
| Introduce a checklist for the check-up | Mortality | ||
| Involve an anesthetist much more this phase | Complications | ||
| More local anesthesia | Mortality | ||
| More procedures in one day or another day for TAVI procedure to shorten the waiting times | None* | ||
| Intervening | Introduce the presence of a surgeon, cardiologist and anesthetist during the procedure | Complications | |
| Use ACIST Pumpc (control of injection rate) | None* | ||
| Only use the new generation of valves (replaceable valves) | Mortality | ||
| Use of a debris catch device | Stroke | ||
| Recovery/Rehab | Introduce clinical pathway | Quality of Life | |
| Ensure removal of the pacemaker the following day and directly implant the long-term pacemaker if needed | Infections | ||
| Apply telemetry monitoring for full period until dismissal | None* | ||
| Monitoring/Managing | Define targets for medication | Re-intervention |
*The proposed potential improvement intervention is not expected to have considerable impact on one of the patient-relevant outcome measures, but process or structure measures
aMECC is minimal extracorporeal circulation
bICU is intensive care unit
cACIST Pump simplifies contract injection for procedures
Monitoring overview
| MONITORING IMPROVEMENT | ||||||||
|---|---|---|---|---|---|---|---|---|
| Treatment | Indicator | Initiative | Based on outcome measures yes/no | How did it take place? | Implementation date | Intended impact on which outcome | Implementation completion (%) | How is it measured? |
| TAVR | 30-day mortality | 1) Pre-TAVR/frailty outpatient clinic started in 2014, 2) TAVR complication discussion started in 4th quarter 2014 with the following issues discussed: A) Choice of valve selection, B) Creation of a specialization team, C) Add additional CT images in report to the TAVI Team. | yes | 1st quarter 2015 | 30-day mortality | 100% | Valve choice: registry measured | |
| 1-year mortality | Pre-TAVR/frailty outpatient clinic started in 2014 | yes | 4th quarter 2014 | 1-year mortality | 100% | Not | ||
| long-term survival | Proposal change training plan - development of online course small private online course for residents with focus on frailty, functional decline and shared decision making | no | specific project team for elderly care | 4th quarter 2015 | none | 0% | Not | |
| Vascular complications | 1) Routine CT scan required pre-TAVR, 2) Start study new closing device in 2015, 3) Start complication discussions in 4th quarter 2014, where it was discussed to lower the threshold for a surgical cut down | yes | 4th quarter 2014 | Vascular complications | 100% | Not | ||
| SAVR | Re-sternotomy | Coagulation policy: Optimization of the transfusion policy based on for example the TEGa at the operation room, or no coagulation correction. In addition, the aim is to reduce the number of blood transfusions. The number of re-sternotomies could decrease at a targeted corrected clotting status of the patient. | no | Initiative from Anesthesiologists who conducted research | 1st quarter 2015 | Bleeding complications | 50% | As part of a study |
aTEG thromboelastography for testing the efficiency of blood coagulation
Fig. 5The Intervention Selection Toolbox (IST). The IST presents steps for two phases for identifying and selection improvement interventions based on patient-relevant outcome measures